# A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis

> **NCT02309359** · PHASE2 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 345 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** ALX-0061
- **OTHER:** Placebo
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02309359
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2019-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02309359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02309359, "A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02309359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*